Daily BriefsIndia

Daily Brief India: Raymond Lifestyle, SMPP Ltd, Ravi Infrabuild Projects Ltd, Biocon Biologics India, UPL Ltd and more

In today’s briefing:

  • Raymond Lifestyle: Governance Crisis?
  • SMPP Ltd Pre-IPO – In the Right Space (Defence), at the Right Time but Growth Has Been Inconsistent
  • Ravi Infrabuild Projects Ltd Pre-IPO Tearsheet
  • Biocon Biologics – Earnings Flash – Q4 And FY 2024-25 Results – Lucror Analytics
  • UPL Limited – Earnings Flash – FY 2024-25 Results – Lucror Analytics


Raymond Lifestyle: Governance Crisis?

By Nimish Maheshwari

  • Raymond Lifestyle’s stock plummets 60% in six months post-demerger, due to lots of governance lapses.
  • Corporate Governance Crisis: CEO,CFO, Director Resignations, Delayed disclosures, Controversial Remuneration and Many More.
  • The company gave excuses such as inflation, an IT incident, etc. in their management meeting after not being able to deliver the performance.

SMPP Ltd Pre-IPO – In the Right Space (Defence), at the Right Time but Growth Has Been Inconsistent

By Sumeet Singh

  • SMPP Ltd is planning to raise about US$476m through its upcoming IPO in India.
  • SMPP Ltd. designs and manufactures defence equipment, specialising in ammunition components and personal protection products for the Indian armed forces, police, and security agencies.
  • In this note, we look at the company’s past performance.

Ravi Infrabuild Projects Ltd Pre-IPO Tearsheet

By Rosita Fernandes

  • Ravi Infrabuild Projects Ltd (1607447D IN)  (RIPL) is looking to raise about US$178m in its upcoming India IPO. The bookrunners for the deal are Axis, Motilal.
  • RIPL is one of the leading infrastructure construction firms in India, experienced in executing structural projects such as flyovers, bridges, railways, highways, and expressways.
  • RIPL had grown 16.6x in terms of its average order size, reaching INR2,577m (as on Dec 2024), as per the company.

Biocon Biologics – Earnings Flash – Q4 And FY 2024-25 Results – Lucror Analytics

By Trung Nguyen

  • Biocon Limited’s Q4 and FY 2024-25 results were solid in our view, with robust growth, stable profitability, as well as improved working capital and cash flows.
  • The balance sheet has strengthened, and liquidity is adequate.

UPL Limited – Earnings Flash – FY 2024-25 Results – Lucror Analytics

By Trung Nguyen

  • UPL Limited’s Q4 and FY 2024-25 results reflected robust revenue growth, substantial margin expansion, a return to profitability and significant debt reduction.
  • This was supported by strong operational execution and strategic initiatives across its global markets.
  • Leverage improved significantly, on account of much lower net debt and higher earnings.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars